Transcervical Fibroid Ablation (TFA): Current Status and New Developments

Transcervical fibroid ablation offers a non-invasive alternative to traditional surgical options for the treatment of symptomatic uterine fibroids using real-time visualization using intrauterine ultrasound guidance.

To review the recent clinical literature on transcervical fibroid ablation (TFA) with the Sonata^® System and discuss new developments in the use of such technology.

Nearly six years since the Food and Drug Administration (FDA) approval in the United States (2018) and 14 years since receiving CE Mark in Europe, TFA with the Sonata system has been used to treat over 30,000 myomas in more than 10,000 procedures world-wide. Data regarding pregnancy outcomes, timing of pregnancy, route of delivery, neoadjuvant use of GnRH analogues and whether TFA is an effective treatment for adenomyosis remain fertile areas for investigation. Significant complications have been rarely reported.